(Q36684024)

15 August 2017

Control of plasma glucose with somatostatin analogue (SMS 201-995) during surgical removal of insulinomas (English)

1 reference

15 August 2017

Utas C

1

1 reference

15 August 2017

Kelestimur F

series ordinal

2

1 reference

15 August 2017

Boyaci A

series ordinal

3

1 reference

15 August 2017

Saglam A

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 1993

1 reference

Postgraduate Medical Journal

15 August 2017

1 reference

15 August 2017

69

1 reference

15 August 2017

818

1 reference

15 August 2017

920-921

1 reference

Clinical review 42: Hypoglycemias

15 August 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2400022

Continuous monitoring and control of plasma glucose during operation for removal of insulinomas

30 September 2017

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2400022

Calcium antagonists and hormone release. I. Effects of verapamil on insulin release in normal subjects and patients with islet-cell tumor

30 September 2017

1 reference

12 December 2020

On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma

1 reference

12 December 2020

Malignant insulinoma: is combined treatment with verapamil and the long-acting somatostatin analogue octreotide (SMS 201-995) more effective than single therapy with either drug?

1 reference

12 December 2020

Malignant insulinoma: effects of a somatostatin analog (compound 201-995) on serum glucose, growth, and gastro-entero-pancreatic hormones

1 reference

12 December 2020

Identifiers

DOI

10.1136/PGMJ.69.818.920

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

8121865

1 reference